LU92393I2 - Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate - Google Patents

Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate Download PDF

Info

Publication number
LU92393I2
LU92393I2 LU92393C LU92393C LU92393I2 LU 92393 I2 LU92393 I2 LU 92393I2 LU 92393 C LU92393 C LU 92393C LU 92393 C LU92393 C LU 92393C LU 92393 I2 LU92393 I2 LU 92393I2
Authority
LU
Luxembourg
Prior art keywords
salt
glycopyrronium
indacaterol
combined
maleate
Prior art date
Application number
LU92393C
Other languages
English (en)
French (fr)
Original Assignee
Sosei R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889490&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92393(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sosei R&D Ltd filed Critical Sosei R&D Ltd
Publication of LU92393I2 publication Critical patent/LU92393I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
LU92393C 2000-04-07 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate LU92393I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008660.3A GB0008660D0 (en) 2000-04-07 2000-04-07 The treatment of respiratory diseases

Publications (1)

Publication Number Publication Date
LU92393I2 true LU92393I2 (fr) 2015-11-02

Family

ID=9889490

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92166C LU92166I2 (fr) 2000-04-07 2013-03-13 Glycopyrronium ou un de ses sels
LU92393C LU92393I2 (fr) 2000-04-07 2014-03-07 Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU92166C LU92166I2 (fr) 2000-04-07 2013-03-13 Glycopyrronium ou un de ses sels

Country Status (25)

Country Link
US (3) US7229607B2 (xx)
EP (3) EP1267866B2 (xx)
JP (1) JP5042426B2 (xx)
CN (3) CN1292745C (xx)
AT (1) ATE330585T2 (xx)
AU (2) AU2004242450B2 (xx)
BE (1) BE2013C023I2 (xx)
BR (1) BR0109875A (xx)
CA (1) CA2405705C (xx)
CY (1) CY1105120T1 (xx)
DE (1) DE60120936T3 (xx)
DK (1) DK1267866T4 (xx)
ES (2) ES2687751T3 (xx)
GB (1) GB0008660D0 (xx)
HK (1) HK1050846B (xx)
HU (2) HU230958B1 (xx)
IL (2) IL151791A0 (xx)
LU (2) LU92166I2 (xx)
MX (1) MXPA02009718A (xx)
NO (3) NO336142B1 (xx)
NZ (2) NZ535284A (xx)
PL (1) PL364024A1 (xx)
PT (1) PT1267866E (xx)
WO (1) WO2001076575A2 (xx)
ZA (1) ZA200207420B (xx)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP2298279B1 (en) 2000-11-30 2018-11-14 Vectura Limited Pharmaceutical compositions for inhalation
ES2334642T5 (es) 2000-11-30 2016-03-07 Vectura Limited Partículas para usar en una composición farmacéutica
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
JP4510383B2 (ja) 2001-05-23 2010-07-21 田辺三菱製薬株式会社 軟骨疾患修復治療用組成物
US20040146561A1 (en) 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
US8557804B2 (en) 2002-03-25 2013-10-15 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
EP1660661A2 (en) * 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005048985A2 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
AU2005210086A1 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
CN101518532A (zh) * 2004-02-06 2009-09-02 Meda制药有限及两合公司 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合
WO2005074918A1 (en) 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
WO2005074900A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
EP1720577A2 (en) * 2004-02-27 2006-11-15 Altana Pharma AG Ciclesonide and glycopyrronium combination
EP1737499A4 (en) * 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP2008504341A (ja) * 2004-06-29 2008-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ステロイドと抗コリン作用剤とを含む吸入用薬剤
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
US9061027B2 (en) 2004-08-27 2015-06-23 Board Of Regents, The University Of Texas System Enhanced delivery of drug compositions to treat life threatening infections
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
PL1863476T3 (pl) 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
EP1861361A1 (en) * 2005-03-24 2007-12-05 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use
US20070148211A1 (en) * 2005-12-15 2007-06-28 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
EP1971369B1 (en) 2005-12-21 2009-08-19 MEDA Pharma GmbH & Co. KG Combination of r,r-glycopyrrolate, rolipram and budesonide for the treatment of inflammatory diseases
GB2434098A (en) * 2005-12-23 2007-07-18 Novartis Ag Process for the preparation of an inhalable dry powder formulation
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CN101896162B (zh) * 2007-12-13 2013-06-05 诺瓦提斯公司 有机化合物
PL2229148T3 (pl) * 2007-12-13 2014-08-29 Novartis Ag Sposób otrzymywania krystalicznych cząstek stałych substancji leczniczej
EP3311820A1 (en) 2008-02-26 2018-04-25 Sunovion Respiratory Development Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP3578169A1 (en) 2009-02-26 2019-12-11 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2763939A1 (en) * 2009-05-29 2010-12-02 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting b2 adrenergic receptor agonists and associated methods and systems
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
BR112012015334A2 (pt) 2009-12-23 2016-03-15 Chiesi Farma Spa terapia combinada para doença pulmonar obstrutiva crônica
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
EP2515856B1 (en) 2009-12-23 2014-04-02 Chiesi Farmaceutici S.p.A. Aerosol Formulation for COPD
EP2515855B3 (en) 2009-12-23 2023-05-03 Chiesi Farmaceutici S.p.A. Combination therapy for COPD
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CA2879317C (en) 2011-08-01 2019-01-15 Monash University Method and formulation for inhalation
WO2013130767A1 (en) 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
KR102391332B1 (ko) 2013-03-15 2022-04-26 펄 테라퓨틱스 인코포레이티드 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
EP3082708B1 (en) * 2013-12-17 2019-04-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants
EP3384898A1 (en) 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
TN2017000077A1 (en) 2014-09-09 2018-07-04 Vectura Ltd Formulation comprising glycopyrrolate, method and apparatus
RS58897B1 (sr) * 2014-09-15 2019-08-30 Verona Pharma Plc Tečna inhalaciona formulacija koja sadrži rpl554
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
CN108024967B (zh) * 2015-06-15 2021-12-21 库姆制药有限责任公司 格隆铵脂肪酸盐及其制备方法
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
IL293328A (en) 2019-12-02 2022-07-01 Chiesi Farm Spa Stainless steel canister for pressurized metered dose inhalers

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SA95160463B1 (ar) * 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5690374A (en) * 1996-04-19 1997-11-25 Nor-Easter Enterprises, Inc. Shock-absorbing tool handle
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
NZ336202A (en) * 1996-11-11 2000-10-27 Christian R Noe Pure enantiomer aryl-cycloalkyl-hydroxycarboxylic acid esters and use in treating smooth muscle spasms and respiritory diseases
CA2277801C (en) * 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
AU718967B2 (en) * 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
EP1100465B1 (de) * 1998-07-24 2004-11-24 Jago Research Ag Medizinische aerosolformulierungen
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
PT1283036E (pt) * 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
US6406745B1 (en) * 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
AU7389300A (en) * 1999-08-02 2001-02-19 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
US6758795B2 (en) 2000-08-22 2004-07-06 Stephen Barber Adjustable water-fillable exercise weights
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
TWI509631B (zh) 2011-02-25 2015-11-21 Henkel IP & Holding GmbH 用於電子裝置之可燒結銀薄片黏著劑

Also Published As

Publication number Publication date
CA2405705C (en) 2011-06-07
CN1292745C (zh) 2007-01-03
NO20024708L (no) 2002-10-24
CY1105120T1 (el) 2010-03-03
ZA200207420B (en) 2003-09-16
NO336142B1 (no) 2015-05-26
NO20024708D0 (no) 2002-10-01
US20050019271A1 (en) 2005-01-27
DE60120936T2 (de) 2006-11-02
US20080220073A1 (en) 2008-09-11
AU776913B2 (en) 2004-09-23
EP2193791A1 (en) 2010-06-09
ATE330585T2 (de) 2006-07-15
CN1720995A (zh) 2006-01-18
EP1449528B1 (en) 2018-08-08
ES2687751T3 (es) 2018-10-29
PL364024A1 (en) 2004-11-29
CN101181263B (zh) 2011-07-06
LU92166I2 (fr) 2014-03-13
JP5042426B2 (ja) 2012-10-03
HUS1900056I1 (hu) 2020-02-28
US7368104B2 (en) 2008-05-06
EP1267866A2 (en) 2003-01-02
ES2266242T5 (es) 2016-10-04
PT1267866E (pt) 2006-10-31
NZ521476A (en) 2004-10-29
ES2266242T3 (es) 2007-03-01
AU2010200660B2 (en) 2012-04-19
AU2004242450B2 (en) 2010-06-03
NZ535284A (en) 2006-04-28
AU8930601A (en) 2001-10-23
HK1050846B (zh) 2007-01-26
AU2004242450A1 (en) 2005-01-20
HK1050846A1 (en) 2003-07-11
DE60120936T3 (de) 2016-11-17
CN101181263A (zh) 2008-05-21
NO2015024I2 (no) 2015-11-25
EP1267866B1 (en) 2006-06-21
BE2013C023I2 (xx) 2020-06-24
DK1267866T4 (en) 2016-10-03
CN1422154A (zh) 2003-06-04
BR0109875A (pt) 2004-07-20
EP1267866B2 (en) 2016-07-20
US7229607B2 (en) 2007-06-12
WO2001076575A2 (en) 2001-10-18
DE60120936D1 (de) 2006-08-03
GB0008660D0 (en) 2000-05-31
US20030068280A1 (en) 2003-04-10
JP2003530344A (ja) 2003-10-14
HU230958B1 (hu) 2019-06-28
DK1267866T3 (da) 2006-10-23
US8029768B2 (en) 2011-10-04
IL151791A0 (en) 2003-04-10
NO2015025I1 (no) 2015-12-07
WO2001076575A3 (en) 2002-03-28
EP1449528A1 (en) 2004-08-25
IL151791A (en) 2015-05-31
NO2015024I1 (no) 2015-11-25
AU2010200660A1 (en) 2010-03-11
CA2405705A1 (en) 2001-10-18
HUP0301518A2 (hu) 2003-08-28
MXPA02009718A (es) 2003-05-27

Similar Documents

Publication Publication Date Title
LU92393I2 (fr) Glycopyrronium ou un sel de celui-ci, plus particulièrement le sel bromure, combiné à indacatérol ouun sel de celui-ci, plus particulièrement le sel maléate
MXPA02011311A (es) Composicion novedosa.
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
ME00520B (me) Levodop/karbidop/entakapon farmaceutski preparat
CA2388142A1 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
IL167900A (en) Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
DE60332629D1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
NO330934B1 (no) Flytende farmasoytisk preparat samt anvendelse og fremstilling derav.
EA200400444A1 (ru) Композиции для лечения простуды
NO20025220D0 (no) Ny fremgangsmÕte
EE200100335A (et) 4-(aminometüül)piperidiinbensamiidid, vaheühendid, farmatseutiline kompositsioon ja nende valmistamismeetodid
MXPA04008152A (es) Compuestos azabiciclicos para el tratamiento de enfermedades.
BRPI0411085A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de vìrus oncogênicos, e de condições ou distúrbios devidos a infecção por hpv
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
EA200300152A1 (ru) Фармацевтический препарат сальметерола и пропионата флутиказона
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
CL2004000805A1 (es) Compuestos derivados de 7-aza-quinazolina sustituida, inhibidores de quinasa p38; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar artritis, enfermedad de crohn, alzheimer, asma, ataque al corazon.
SE0000303D0 (sv) Novel compounds
ATE415393T1 (de) Neue piperidinylderivate als modulatoren der aktivität des chemokinrezeptors
MY128882A (en) Novel use of substituted aminomethyl chromans